The expanded age indication for VAQTA is good news for parents, doctors and the public health community because it means we can help protect children against hepatitis A earlier in life.
Study Supports Use of VAQTA Starting at 12 Months of Age
The younger age indication for VAQTA is supported by the results of an open-label study of children with no evidence of hepatitis A infection.
In this study of 617 children 12-23 months of age, 343 children were evaluated for indicators of an immune response to VAQTA after the second dose of a two dose series.
25U) of VAQTA alone or in combination with other routinely recommended pediatric vaccines, the most commonly reported complaints (>2 percent of injections) after one or both of the doses of VAQTA were localized injection-site reactions (pain/tenderness/soreness), fever, diarrhea, vomiting, irritability, upper respiratory infection, rhinorrhea, cough, rash and otitis media.
As with any vaccine, vaccination with VAQTA may not result in a protective response in all people.
As with any vaccine, there is the possibility that use of VAQTA in very large populations might reveal adverse experiences not observed in clinical trials.
For details about the indications, contraindications, warnings, precautions, adverse reactions and dosage and administration for VAQTA, please read the attached prescribing information.